Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.72 |
| ▸ | AURKA | O14965 | 2/20 | 0.72 |
| ▸ | CDK1 | P06493 | 1/20 | 0.72 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.72 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 17/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13938464 | 0.95 | KIT (0.65) | KITAURKACDK1MAP2K6PDGFRA | |
| SCHEMBL13938482 | 0.91 | KIT (0.63) | KITAURKACDK1MAP2K6PDGFRA | |
| SCHEMBL13938509 | 0.91 | KIT (0.63) | KITAURKACDK1MAP2K6PDGFRA | |
| SCHEMBL13938529 | 0.89 | KIT (0.61) | KITAURKACDK1MAP2K6PDGFRA | |
| SCHEMBL13938465 | 0.89 | KIT (0.56) | KITAURKACDK1MAP2K6PDGFRA | |
| SCHEMBL13938545 | 0.88 | KIT (0.80) | KITAURKACDK1MAP2K6PDGFRA | |
| SCHEMBL13938535 | 0.87 | KIT (0.79) | KITAURKACDK1MAP2K6PDGFRA | |
| SCHEMBL13938359 | 0.86 | KIT (0.68) | KITAURKACDK1MAP2K6PDGFRA | |
| SCHEMBL13938455 | 0.86 | KIT (0.54) | KITAURKACDK1MAP2K6PDGFRA | |
| SCHEMBL14098769 | 0.86 | KIT (0.82) | KITAURKACDK1MAP2K6PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029982-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090029982-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008055233-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | ERBB3, ERBB2, AXL | KIT 960/4885AURKA 5/4885CDK1 14/4885 |
| US-20090029982-A1 | PROTEIN KINASE INHIBITORS | CDK2, PACSIN2, AKT1 | KIT 1337/4885AURKA 339/4885CDK1 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.